Abgenix - ein interessanter Wert - 500 Beiträge pro Seite
eröffnet am 17.01.00 20:26:22 von
neuester Beitrag 04.05.01 18:43:31 von
neuester Beitrag 04.05.01 18:43:31 von
Beiträge: 40
ID: 51.882
ID: 51.882
Aufrufe heute: 0
Gesamt: 2.087
Gesamt: 2.087
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 10 Minuten | 2255 | |
| vor 1 Stunde | 2047 | |
| vor 29 Minuten | 1772 | |
| vor 11 Minuten | 1460 | |
| vor 6 Minuten | 1294 | |
| vor 14 Minuten | 1108 | |
| 08.05.24, 11:56 | 1037 | |
| vor 4 Minuten | 862 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.860,35 | -0,08 | 225 | |||
| 2. | 2. | 4,5200 | -10,25 | 159 | |||
| 3. | 3. | 6,8720 | -0,72 | 87 | |||
| 4. | 5. | 0,2460 | +3,36 | 85 | |||
| 5. | 4. | 0,2000 | -1,48 | 73 | |||
| 6. | 7. | 160,72 | +0,55 | 49 | |||
| 7. | 6. | 5,7200 | +2,14 | 49 | |||
| 8. | 10. | 16,000 | -0,62 | 48 |
Feedback
Hallo zusammen,
ich möchte hier auch mal meinen heißen Tip abgeben. Schaut Euch mal die Fa. Abgenix an. Hier wird immer nur über Medarex diskutiert, welche anscheinend ähnliche Mäuse hat.
Abgenix hat als Technik die "Xenomaus" an der sie nun die alleinigen Rechte besitzt. Die Xenomaus hat z.T. ein menschliches Immunsystem, welches 100% humane Antikörper herstellt. Die Gene zur Produktion von Maus-Antikörpern wurden unterdrückt.
Damit hat Abgenix ein exzellentes Mittel in der Hand, um gegen beliebige Moleküle humane Antikörper herzustellen. Dies eröffnet ungeahnte Möglichkeiten für neue Medikamente. Siehe hierzu z.B. auch die Medikamente von Medimmune, welche derzeit einen durchschlagenden Erfolg haben und auch auf humanen Antikörpern basieren.
Für nähere Infos: www.abgenix.com
Abgenix wird von den Analysten jedenfalls äußerst gut bewertet. Abgenix soll bereits nächstes Jahr in die Gewinnzone kommen.
Im Anhang noch ein Ausschnitt von Abgenix:
___________________________________________________________________
The company`s approach to generating human antibodies with fully human protein sequences is to use genetically engineered strains of mice in which mouse antibody gene expression is suppressed and functionally replaced with human antibody gene expression, while leaving intact the rest of the mouse immune system. Rather than engineering each antibody product candidate, these transgenic mice capitalize on the natural power of the mouse immune system in surveillance and affinity maturation to produce a broad repertoire of high affinity antibodies. By introducing human antibody genes into the mouse genome, transgenic mice with such traits can be bred indefinitely. Importantly, these transgenic mice are capable of generating human antibodies to human antigens because the only human products expressed in the mice (and therefore recognized as "self") are the antibodies themselves. Any other human tissue or protein is thus recognized as a foreign antigen by the mouse and an immune response will be mounted.
Abnormal production of certain human proteins, such as cytokines and growth factors or their receptors, have been implicated in various human diseases. Neutralization or elimination of these abnormally produced or regulated human proteins with the use of human antibodies could ameliorate or suppress the target disease. Therefore, the ability of these transgenic mice to generate human antibodies against human antigens could offer an advantage to drug developers compared with some of the other approaches described previously. A challenge with this approach, however, has been to introduce enough of the human antibody genes in appropriate configuration into the mouse genome to ensure that these mice are capable of recognizing the broad diversity of antigens relevant for human therapies.
To make its transgenic mice a robust tool capable of consistently generating high affinity antibodies that can recognize a broad range of antigens, Abgenix equipped its XenoMouse with approximately 80% of the human heavy chain antibody genes and a significant amount of the human light chain genes. The complex assembly of these genes together with their semi-random pairing allows XenoMouse to recognize a diverse repertoire of antigen structures. XenoMouse technology further capitalizes on the natural in vivo affinity maturation process to generate high affinity, fully human antibodies. In addition, Abgenix has developed multiple strains of XenoMouse, each of which is capable of producing a different class of antibody to perform different therapeutic functions. Abgenix believes that its various XenoMouse strains will provide maximum flexibility for drug developers in generating antibodies of the specific type best suited for a given disease indication.
Abgenix believes that its XenoMouse technology offers the following advantages: (i) producing antibodies with fully human protein sequences; (ii) generating a diverse antibody response to essentially any disease target appropriate for antibody therapy; (iii) generating high affinity antibodies which do not require further engineering; (iv) enabling more efficient product development; and (v) providing flexibility in choosing manufacturing processes.
Recent advances in the technologies for creating and producing antibody products coupled with a better understanding of how antibodies and the immune system function in key disease states have led to renewed interest in the commercial development of antibodies as therapeutic products. According to a recent survey by the Pharmaceutical Research and Manufacturers of America, antibodies account for over 20% of all biopharmaceutical products in clinical development. In addition, eight monoclonal antibody products are being marketed as of December 31, 1998, for the treatment of a wide range of medical disorders.
Abgenix believes that, as products, antibodies have several potential clinical and commercial advantages over traditional therapies. These include:
faster product development;
fewer unwanted side effects as a result of high specificity for the disease target;
greater patient compliance and higher efficacy as a result of favorable pharmacokinetics;
delivery of various payloads, including drugs, radiation and toxins, to specific disease sites; and
ability to elicit a desired immune response.
Limitations of Current Approaches to Development of Antibody Products
Despite the early recognition of antibodies as promising therapeutic agents, most approaches thus far to developing them as products have met with a number of commercial and technical limitations. Initial efforts were aimed at the development of hybridoma cells, which are immortalized mouse antibody-secreting B cells. Such hybridoma cells are derived from normal mouse B cells that have been genetically manipulated so that they are capable of reproducing over an indefinite period of time. They are then cloned to produce a homogeneous population of identical cells which produce one single type of mouse antibody capable of recognizing one specific antigen ("monoclonal antibody").
While mouse monoclonal antibodies can be generated to bind to a number of antigens, they contain mouse protein sequences and tend to be recognized as foreign by the human immune system. As a result, they are quickly eliminated by the human body and have to be administered frequently. When patients are repeatedly treated with mouse antibodies, they will begin to produce antibodies that effectively neutralize the mouse antibody, a reaction referred to as a Human Anti-Mouse Antibody ("HAMA") response. In many cases, the HAMA response prevents the mouse antibodies from having the desired therapeutic effect and may cause the patient to have an allergic reaction.
Recognizing the limitations of mouse monoclonal antibodies, researchers have developed a number of approaches to make them appear more human-like to a patient`s immune system. For example, improved forms of mouse antibodies, referred to as "chimeric" and "humanized" antibodies, are genetically engineered and assembled from portions of mouse and human antibody gene fragments. While such chimeric and humanized antibodies are more human-like, they still retain a varying amount of the mouse antibody protein sequence and, accordingly, may continue to trigger the HAMA response. Additionally, the humanization process can be expensive and time consuming, requiring at least months and sometimes over a year of secondary manipulation after the initial generation of the mouse antibody. Once the humanization process is complete, the remodeled antibody gene must then be expressed in a recombinant cell line appropriate for antibody manufacturing, adding additional time before the production of preclinical and clinical material can be initiated. In addition, the combination of mouse and human antibody gene fragments can result in a final antibody product which is different in structure from the original mouse antibody, leading to a decrease in specificity or a loss in affinity.
ich möchte hier auch mal meinen heißen Tip abgeben. Schaut Euch mal die Fa. Abgenix an. Hier wird immer nur über Medarex diskutiert, welche anscheinend ähnliche Mäuse hat.
Abgenix hat als Technik die "Xenomaus" an der sie nun die alleinigen Rechte besitzt. Die Xenomaus hat z.T. ein menschliches Immunsystem, welches 100% humane Antikörper herstellt. Die Gene zur Produktion von Maus-Antikörpern wurden unterdrückt.
Damit hat Abgenix ein exzellentes Mittel in der Hand, um gegen beliebige Moleküle humane Antikörper herzustellen. Dies eröffnet ungeahnte Möglichkeiten für neue Medikamente. Siehe hierzu z.B. auch die Medikamente von Medimmune, welche derzeit einen durchschlagenden Erfolg haben und auch auf humanen Antikörpern basieren.
Für nähere Infos: www.abgenix.com
Abgenix wird von den Analysten jedenfalls äußerst gut bewertet. Abgenix soll bereits nächstes Jahr in die Gewinnzone kommen.
Im Anhang noch ein Ausschnitt von Abgenix:
___________________________________________________________________
The company`s approach to generating human antibodies with fully human protein sequences is to use genetically engineered strains of mice in which mouse antibody gene expression is suppressed and functionally replaced with human antibody gene expression, while leaving intact the rest of the mouse immune system. Rather than engineering each antibody product candidate, these transgenic mice capitalize on the natural power of the mouse immune system in surveillance and affinity maturation to produce a broad repertoire of high affinity antibodies. By introducing human antibody genes into the mouse genome, transgenic mice with such traits can be bred indefinitely. Importantly, these transgenic mice are capable of generating human antibodies to human antigens because the only human products expressed in the mice (and therefore recognized as "self") are the antibodies themselves. Any other human tissue or protein is thus recognized as a foreign antigen by the mouse and an immune response will be mounted.
Abnormal production of certain human proteins, such as cytokines and growth factors or their receptors, have been implicated in various human diseases. Neutralization or elimination of these abnormally produced or regulated human proteins with the use of human antibodies could ameliorate or suppress the target disease. Therefore, the ability of these transgenic mice to generate human antibodies against human antigens could offer an advantage to drug developers compared with some of the other approaches described previously. A challenge with this approach, however, has been to introduce enough of the human antibody genes in appropriate configuration into the mouse genome to ensure that these mice are capable of recognizing the broad diversity of antigens relevant for human therapies.
To make its transgenic mice a robust tool capable of consistently generating high affinity antibodies that can recognize a broad range of antigens, Abgenix equipped its XenoMouse with approximately 80% of the human heavy chain antibody genes and a significant amount of the human light chain genes. The complex assembly of these genes together with their semi-random pairing allows XenoMouse to recognize a diverse repertoire of antigen structures. XenoMouse technology further capitalizes on the natural in vivo affinity maturation process to generate high affinity, fully human antibodies. In addition, Abgenix has developed multiple strains of XenoMouse, each of which is capable of producing a different class of antibody to perform different therapeutic functions. Abgenix believes that its various XenoMouse strains will provide maximum flexibility for drug developers in generating antibodies of the specific type best suited for a given disease indication.
Abgenix believes that its XenoMouse technology offers the following advantages: (i) producing antibodies with fully human protein sequences; (ii) generating a diverse antibody response to essentially any disease target appropriate for antibody therapy; (iii) generating high affinity antibodies which do not require further engineering; (iv) enabling more efficient product development; and (v) providing flexibility in choosing manufacturing processes.
Recent advances in the technologies for creating and producing antibody products coupled with a better understanding of how antibodies and the immune system function in key disease states have led to renewed interest in the commercial development of antibodies as therapeutic products. According to a recent survey by the Pharmaceutical Research and Manufacturers of America, antibodies account for over 20% of all biopharmaceutical products in clinical development. In addition, eight monoclonal antibody products are being marketed as of December 31, 1998, for the treatment of a wide range of medical disorders.
Abgenix believes that, as products, antibodies have several potential clinical and commercial advantages over traditional therapies. These include:
faster product development;
fewer unwanted side effects as a result of high specificity for the disease target;
greater patient compliance and higher efficacy as a result of favorable pharmacokinetics;
delivery of various payloads, including drugs, radiation and toxins, to specific disease sites; and
ability to elicit a desired immune response.
Limitations of Current Approaches to Development of Antibody Products
Despite the early recognition of antibodies as promising therapeutic agents, most approaches thus far to developing them as products have met with a number of commercial and technical limitations. Initial efforts were aimed at the development of hybridoma cells, which are immortalized mouse antibody-secreting B cells. Such hybridoma cells are derived from normal mouse B cells that have been genetically manipulated so that they are capable of reproducing over an indefinite period of time. They are then cloned to produce a homogeneous population of identical cells which produce one single type of mouse antibody capable of recognizing one specific antigen ("monoclonal antibody").
While mouse monoclonal antibodies can be generated to bind to a number of antigens, they contain mouse protein sequences and tend to be recognized as foreign by the human immune system. As a result, they are quickly eliminated by the human body and have to be administered frequently. When patients are repeatedly treated with mouse antibodies, they will begin to produce antibodies that effectively neutralize the mouse antibody, a reaction referred to as a Human Anti-Mouse Antibody ("HAMA") response. In many cases, the HAMA response prevents the mouse antibodies from having the desired therapeutic effect and may cause the patient to have an allergic reaction.
Recognizing the limitations of mouse monoclonal antibodies, researchers have developed a number of approaches to make them appear more human-like to a patient`s immune system. For example, improved forms of mouse antibodies, referred to as "chimeric" and "humanized" antibodies, are genetically engineered and assembled from portions of mouse and human antibody gene fragments. While such chimeric and humanized antibodies are more human-like, they still retain a varying amount of the mouse antibody protein sequence and, accordingly, may continue to trigger the HAMA response. Additionally, the humanization process can be expensive and time consuming, requiring at least months and sometimes over a year of secondary manipulation after the initial generation of the mouse antibody. Once the humanization process is complete, the remodeled antibody gene must then be expressed in a recombinant cell line appropriate for antibody manufacturing, adding additional time before the production of preclinical and clinical material can be initiated. In addition, the combination of mouse and human antibody gene fragments can result in a final antibody product which is different in structure from the original mouse antibody, leading to a decrease in specificity or a loss in affinity.
Hi ihr Kohlenstoffeinheiten,
ich habe diesen Wert noch für 45 $ kaufen können und halte ihn auch noch. In letzter Zeit hat sich allerdings nicht mehr viel bewegt. Er schwankt so zwischen 120 und 150 $. Er hat jetzt aktuell 200% plus, d.h. seit seinem Senkrechtstart im November. Ich denke, bei der Nachfrage nach Biotech und den Aussichten von Abgenix, dürfte ein Kursziel von 300 $ bald erreicht sein, durch die erworbenen Lizenzen und präsentierten Zwischenergebnisse ist noch viel Phantasie im Wert. Die Analysten bewerten den wert nicht nur gut, sondern strong buy.
CU
ich habe diesen Wert noch für 45 $ kaufen können und halte ihn auch noch. In letzter Zeit hat sich allerdings nicht mehr viel bewegt. Er schwankt so zwischen 120 und 150 $. Er hat jetzt aktuell 200% plus, d.h. seit seinem Senkrechtstart im November. Ich denke, bei der Nachfrage nach Biotech und den Aussichten von Abgenix, dürfte ein Kursziel von 300 $ bald erreicht sein, durch die erworbenen Lizenzen und präsentierten Zwischenergebnisse ist noch viel Phantasie im Wert. Die Analysten bewerten den wert nicht nur gut, sondern strong buy.
CU
Abgenix wird im Jahr 2000 eine der Biotech-Raketen sein.
STRONG BUY.
Mein Kursziel: 350-400E!
STRONG BUY.
Mein Kursziel: 350-400E!
medarex nicht vergessen - von abgenix geht geht auch medarex
Medarex ging die letzten Wochen fantastisch. Ich glaube, die nächste
Zeit (1-2 Monate) macht Abgenix einige Prozente mehr.
Zeit (1-2 Monate) macht Abgenix einige Prozente mehr.
Trading Spotlight
Hallo zusammen!
Ich habe mir zwar Abgenix gekauft, ich möchte aber dennoch wissen, welches die bessere Firma ist - Medarex oder Abgenix.
Da derzeit beide Firmen noch keine direkte Gewinne mit eigenen Produkten erzielen, gelten zur Bewertung andere Kriterien:
-Anzahl der Allianzen mit anderen Firmen (erzielt regelmäßigen Cashflow durch Forschungstätigkeit)
-Wer hat die bessere technologische Basis (welche Antikörper sind herstellbar - Maus-, "chimeric"-, "humanized"-, oder 100% menschlich. In dieser Reihenfolge ist die Qualität zu sehen. Siehe obigen Artikel).
-Prognose wann wird Gewinnzone erreicht
-Steigerungsrate des Umsatzes (=Revenue)
-Bewertung durch Analyten
So wenn nun jeder seine Hausaufgaben macht, können wir uns wieder austauschen und diese Frage entscheiden.
Ich habe mir zwar Abgenix gekauft, ich möchte aber dennoch wissen, welches die bessere Firma ist - Medarex oder Abgenix.
Da derzeit beide Firmen noch keine direkte Gewinne mit eigenen Produkten erzielen, gelten zur Bewertung andere Kriterien:
-Anzahl der Allianzen mit anderen Firmen (erzielt regelmäßigen Cashflow durch Forschungstätigkeit)
-Wer hat die bessere technologische Basis (welche Antikörper sind herstellbar - Maus-, "chimeric"-, "humanized"-, oder 100% menschlich. In dieser Reihenfolge ist die Qualität zu sehen. Siehe obigen Artikel).
-Prognose wann wird Gewinnzone erreicht
-Steigerungsrate des Umsatzes (=Revenue)
-Bewertung durch Analyten
So wenn nun jeder seine Hausaufgaben macht, können wir uns wieder austauschen und diese Frage entscheiden.
Zitate aus WebersWeb (Börse online):
"...Abgenix produziert menschl. Antikörper mit Hilfe von Mäusen - und
koopoeriert bereits mit Top-Pharmakonzernen." (leider keine näheren
Angaben)
"{Abgenix} könnte in einigen Jahren zu den Stars der Biotech-Szene
gehören. Die Aktie ist eine der aussichtsreichsten langfristigen
Biotech-Anlagen." (meine ich auch!!)
22% von Abgenix sind durch die Übernahme von Cell Genesys Inc.durch
Genzyme Corp. in den Besitz der letzteren übergegangen.
"...Abgenix produziert menschl. Antikörper mit Hilfe von Mäusen - und
koopoeriert bereits mit Top-Pharmakonzernen." (leider keine näheren
Angaben)
"{Abgenix} könnte in einigen Jahren zu den Stars der Biotech-Szene
gehören. Die Aktie ist eine der aussichtsreichsten langfristigen
Biotech-Anlagen." (meine ich auch!!)
22% von Abgenix sind durch die Übernahme von Cell Genesys Inc.durch
Genzyme Corp. in den Besitz der letzteren übergegangen.
Oh welche Freude, vielleicht schaffen wir in dieser Woche noch die 200$.
Es ist noch viel Luft und Phantasie in diesem Wert. Ich erhöhe meine Prognose auch auf den Wert nach Locimo von 350-400$.
CU
Es ist noch viel Luft und Phantasie in diesem Wert. Ich erhöhe meine Prognose auch auf den Wert nach Locimo von 350-400$.
CU
Egal, ob diese Woche 200 oder nicht, wir werden noch unsere Freude haben in den nächsten Monaten, Achill.
Ciao, Loci
Ciao, Loci
Hallo Leute
Der Kurs von 200 Euro wurde nun schon überschritten, sogar fast schon 300 Euro erreicht. Die Wachstumstory beginnt gerade erst.
Im Vergleich zu Medarex, welche fast die gleiche Technologie hat, ist die Qualität der Firma genauso gut. Die Bewertung ist aber noch deutlich geringer.
Viel Erfolg
Greg1966
Der Kurs von 200 Euro wurde nun schon überschritten, sogar fast schon 300 Euro erreicht. Die Wachstumstory beginnt gerade erst.
Im Vergleich zu Medarex, welche fast die gleiche Technologie hat, ist die Qualität der Firma genauso gut. Die Bewertung ist aber noch deutlich geringer.
Viel Erfolg
Greg1966
Hallo,
Abgenix wurde schon im Börse Online und
heute 21.02.00 im Financial Times empfohlen.
Übrigens bei DWS Biotech Aktien Typ 0 mit
4 % Gewichtung Nummer 1. Siehe dws.de
Kursziel bis Jahresende - 1000 €.
Also kaufen und halten.
Grüße
Abgenix wurde schon im Börse Online und
heute 21.02.00 im Financial Times empfohlen.
Übrigens bei DWS Biotech Aktien Typ 0 mit
4 % Gewichtung Nummer 1. Siehe dws.de
Kursziel bis Jahresende - 1000 €.
Also kaufen und halten.
Grüße
wo hast du die 1000 dollar her ? dein kursziel oder von analysten wenn ja wer?
Hallo,
das Kursziel von 1000 Euro halte ich persönlich durchaus für realistisch. Ja, es wäre sogar bis zur Jahresmitte erreichbar, falls die Aktie weiter so wie bisher stiege. Dies wiederum halte ich nicht für realistisch. Also, bis zum Jarhresende -- ist drin, wenn man das Potential und die vielen Medikamente in der Pipeline berücksichtigt.
Gruß Greg
das Kursziel von 1000 Euro halte ich persönlich durchaus für realistisch. Ja, es wäre sogar bis zur Jahresmitte erreichbar, falls die Aktie weiter so wie bisher stiege. Dies wiederum halte ich nicht für realistisch. Also, bis zum Jarhresende -- ist drin, wenn man das Potential und die vielen Medikamente in der Pipeline berücksichtigt.
Gruß Greg
Hallo Greg1966,
scheinen ja die gleichen Interessen zu haben. Bei Abgenix kann ich nur sagen, zurücklehnen und geniessen. Wir haben bei 36 gekauft. Ueber das Kursziel der Aktie in den naechsten drei Jahren bin ich allerdings noch am gruebeln.
scheinen ja die gleichen Interessen zu haben. Bei Abgenix kann ich nur sagen, zurücklehnen und geniessen. Wir haben bei 36 gekauft. Ueber das Kursziel der Aktie in den naechsten drei Jahren bin ich allerdings noch am gruebeln.
Hallo Leute,
ich schalte mich gerade zum ersten mal in einen WO-Thread ein, mein Heimathafen ist ariva.de, das mit abstand kompetenteste Boeard ;-), schätze aber Eure Diskussionen sehr. Gerade im Biotechbereich seit ihr den Arivanern ein wenig voraus.
Zur Aktie:
Abgenix ist ein absolutes Top-Unternehmen, das sich zurecht Weltmarktführer in res Antikörpern nennen darf, Morphosys ist nur ein billiger, von Frötsch gepushter Idiotenwert.
Nach der Konsolidierung bis auf 280, kann ich nur allen die noch nicht eingestiegen sind zu diesem Schritt raten.
Die genannten 1000 Euro auf Jahressicht kann ich nur Teilen.
Grüße von
TGK
ich schalte mich gerade zum ersten mal in einen WO-Thread ein, mein Heimathafen ist ariva.de, das mit abstand kompetenteste Boeard ;-), schätze aber Eure Diskussionen sehr. Gerade im Biotechbereich seit ihr den Arivanern ein wenig voraus.
Zur Aktie:
Abgenix ist ein absolutes Top-Unternehmen, das sich zurecht Weltmarktführer in res Antikörpern nennen darf, Morphosys ist nur ein billiger, von Frötsch gepushter Idiotenwert.
Nach der Konsolidierung bis auf 280, kann ich nur allen die noch nicht eingestiegen sind zu diesem Schritt raten.
Die genannten 1000 Euro auf Jahressicht kann ich nur Teilen.
Grüße von
TGK
Bin bei Morphosys auch noch sehr skeptisch, habe mich aber schon geärgert, dass ich bei 17 nicht eingestiegen bin.
Falls Morphosys noch einmal Patentprobleme bekommt, hoffe ich das alle hier frühzeitig aus dem Wert kommen.
Frage: Warum hat Abgenix die meisten Partnerschaften?
Totzdem wünsche ich allen Antikörperaktien steigende Kurse, der Markt ist groß genug!
Falls Morphosys noch einmal Patentprobleme bekommt, hoffe ich das alle hier frühzeitig aus dem Wert kommen.
Frage: Warum hat Abgenix die meisten Partnerschaften?
Totzdem wünsche ich allen Antikörperaktien steigende Kurse, der Markt ist groß genug!
IDEC ist günstiger bewertet und macht Gewinne 0,86 $/share
MK bei 5,03 Mrd $
Abgenix ist mit 6,03 mrd $ bewertet und macht -1,41 $/aktie!
IDEC KGV bei nur 138!!
HKTop
MK bei 5,03 Mrd $
Abgenix ist mit 6,03 mrd $ bewertet und macht -1,41 $/aktie!
IDEC KGV bei nur 138!!
HKTop
ABGENIX INC Nasdaq 00339B107 247,125 -64,875 -20,79%
in der neuen finanzen heist es bei jeder schwäche nachkaufen !!
in der neuen finanzen heist es bei jeder schwäche nachkaufen !!
ABGENIX INC Nasdaq 00339B107 238,00 -74,00 -23,72%
was soll der scheiss !!!
was soll der scheiss !!!
Einen Aktiensplit habe ich mir anders vorgestellt.
Stay long, Augen zu und durch!
Stay long, Augen zu und durch!
Black Monday for Biotech!!!!!!!!!1
NAS-> ABGX Abgenix: -28% runter auf 224$
====================================
Volle Deckung!!!!!!
NAS-> ABGX Abgenix: -28% runter auf 224$
====================================
Volle Deckung!!!!!!
Black Monday for Biotech!!!!!!!!!1
NAS-> ABGX Abgenix: -28% runter auf 224$
====================================
Volle Deckung!!!!!!
NAS-> ABGX Abgenix: -28% runter auf 224$
====================================
Volle Deckung!!!!!!
Das war noch nicht das Ende.......
Nasdaq-Schluß: 199$ -36,6%
Ich hab nen Lachkick bekommen.........
weil ich natürlich auch Abgenix(ab geh- nix!) habe.....
Nasdaq-Schluß: 199$ -36,6%
Ich hab nen Lachkick bekommen.........
weil ich natürlich auch Abgenix(ab geh- nix!) habe.....
Robertson Stephens Reiterates Strong Buy Rating on ABGX TUESDAY, MARCH 21, 2000 12:01 PM
- BusinessWire
SAN FRANCISCO, Mar 21, 2000 (BUSINESS WIRE) -- Robertson Stephens Managing Director and Senior Biopharmaceuticals Analyst Jay Silverman today reiterated his Strong Buy rating on Abgenix Inc. (NASDAQ:ABGX).
Abgenix is focused on the development and commercialization of proprietary monoclonal antibodies for pharmaceutical applications, including transplant related conditions, inflammation, autoimmune diseases and cancer.
"We are reiterating our Strong Buy rating on Abgenix," said Silverman. "Yesterday, the European Patent Office revoked broad claims in Protein Design Labs` (PDLI - $134) humanization patent. We believe the European Patent decision has negative implications for PDLI only and is totally unrelated to Abgenix."
"Abgenix patents on creating fully human antibodies via transgenic mice have never been challenged, nor do we expect them to be," said Silverman. "In fact, the majority of new antibodies under development since the XenoMouse became available are being developed by Abgenix and its partners. In our view, Abgenix is an excellent buying opportunity and we reiterate our Strong Buy rating."
Clients interested in receiving more information should contact their salesperson at (415) 781-9700.
Robertson Stephens is the leading full-service investment bank focused exclusively on growth companies. In 1999, the firm completed 218 public offerings and 66 private offerings, raising more than $40 billion in capital for clients. In addition, the firm advised on over 85 M&A transactions in 1999 with an aggregate value in excess of $60 billion. The firm`s 47 equity research analysts cover nearly 700 companies. Founded in 1978, Robertson Stephens (Legal name: FleetBoston Robertson Stephens Inc.) is a section 20 subsidiary of FleetBoston Financial Corporation (NYSE:FBF) and a member of the NASD and all major exchanges. Together, Robertson Stephens, FleetBoston Robertson Stephens International Ltd., and Robertson Stephens Evergreen Securities Ltd. has over 1,000 employees worldwide with offices in Boston, San Francisco, New York, Menlo Park, Chicago, London, Munich and Tel Aviv.
Biotech stocks extend slide after patent setback TUESDAY, MARCH 21, 2000 4:17 PM
- Reuters
NEW YORK, March 21 (Reuters) - Shares of biotechnology companies resumed their steep slide on Tuesday, with Protein Design Labs Inc. (NASDAQ:PDLI) leading the Nasdaq percentage losers after news that one of the drug developer`s European patents had been revoked.
Shares of Protein Design Labs slid 38 percent on the Nasdaq, or 51-15/16, to 82-3/16, by Tuesday afternoon, extending a 26 percent decline by the stock the previous session.
Late Monday, the California drug developer said broad claims on its European patent for humanized monoclonal antibodies had been revoked. It said it planned to press an appeal of the decision over the next several years, during which time the patent decision would be suspended.
The announcement, which came after regular U.S. stock trading, was the latest piece of unfavorable news for a sector that has suffered a sharp setback over the past two weeks. On Tuesday, the Nasdaq biotech index slipped 30.96, or 2.85 percent, at 1056.53, bringing its losses to about 35 percent since March 6. Before then, the index had risen more than 80 percent since the beginning of the year.
The selling pressure spread to a broad range of biotech stocks even though analysts saw no far-reaching negative precedent involved in the European patent ruling and said the outlook for Protein Design Labs remained strong.
"We think this is one of the great all-time buying opportunities, and the event that happened yesterday is completely nonmaterial," said Matthew Geller, senior biotechnology analyst with CIBC World Markets. "The decision has no impact on products sold or manufactured in the United States. So there`s a very questionable dubious impact five or six years from now."
William Tanner, a biotechnology analyst with SG Cowen, said he was still bullish on Protein Design Labs. "We`d upgrade the stock here if we didn`t have a `strong buy` rating on it."
Some analysts, however, thought the Protein Design downturn was unlikely to hurt the sector because the companies use different technologies to make antibodies .
An antibody is a naturally-occurring immune system protein that selectively seeks out and destroys pathogens or other proteins that are deemed "foreign" invaders. They can be harvested and manipulated in the laboratory by so-called recombinant methods for future use as drugs.
Protein Design specializes in making "humanized" antibodies, that have mostly human components, but also traces of mouse antibodies. Abgenix Inc. (NASDAQ:ABGX) and Medarex Inc. (NASDAQ:MEDX) by contrast, grow "fully human" antibodies in mice whose immune systems have been genetically changed to produce antibodies with purely human characteristics and no mouse components.
Antibodies of all types are the rage among drug makers because they are an effective and relatively easy to produce means of treating and preventing disease.
Among other biotech stocks, Myriad Genetics Inc. (NASDAQ:MYGN) was down 44 percent, or 53, at 67; Medarex slid 23 percent, or 15-13/16, to 51; and Antigenics Inc. (NASDAQ:AGEN) was down 24 percent, or 7-1/4, at 22-1/2.
"Everybody was of the consensus that (biotechs) were a little overextended," Tanner said. "The first few months of this year the Nasdaq biotech index went ballistic."
Biotech stocks tumbled last week, falling as much as 14 percent, after U.S. President Bill Clinton and British Prime Minister Tony Blair said scientists worldwide should have free access to research on the mapping of human genes.
Tanner said stocks were now returning to a more realistic value. "It`s not hype so much," he said. "It`s not a house of cards, there`s substance (to the sector)."
War das ein Kniefall, aber solide Unterstützung bei 180, wenigstens das.
TGK
- BusinessWire
SAN FRANCISCO, Mar 21, 2000 (BUSINESS WIRE) -- Robertson Stephens Managing Director and Senior Biopharmaceuticals Analyst Jay Silverman today reiterated his Strong Buy rating on Abgenix Inc. (NASDAQ:ABGX).
Abgenix is focused on the development and commercialization of proprietary monoclonal antibodies for pharmaceutical applications, including transplant related conditions, inflammation, autoimmune diseases and cancer.
"We are reiterating our Strong Buy rating on Abgenix," said Silverman. "Yesterday, the European Patent Office revoked broad claims in Protein Design Labs` (PDLI - $134) humanization patent. We believe the European Patent decision has negative implications for PDLI only and is totally unrelated to Abgenix."
"Abgenix patents on creating fully human antibodies via transgenic mice have never been challenged, nor do we expect them to be," said Silverman. "In fact, the majority of new antibodies under development since the XenoMouse became available are being developed by Abgenix and its partners. In our view, Abgenix is an excellent buying opportunity and we reiterate our Strong Buy rating."
Clients interested in receiving more information should contact their salesperson at (415) 781-9700.
Robertson Stephens is the leading full-service investment bank focused exclusively on growth companies. In 1999, the firm completed 218 public offerings and 66 private offerings, raising more than $40 billion in capital for clients. In addition, the firm advised on over 85 M&A transactions in 1999 with an aggregate value in excess of $60 billion. The firm`s 47 equity research analysts cover nearly 700 companies. Founded in 1978, Robertson Stephens (Legal name: FleetBoston Robertson Stephens Inc.) is a section 20 subsidiary of FleetBoston Financial Corporation (NYSE:FBF) and a member of the NASD and all major exchanges. Together, Robertson Stephens, FleetBoston Robertson Stephens International Ltd., and Robertson Stephens Evergreen Securities Ltd. has over 1,000 employees worldwide with offices in Boston, San Francisco, New York, Menlo Park, Chicago, London, Munich and Tel Aviv.
Biotech stocks extend slide after patent setback TUESDAY, MARCH 21, 2000 4:17 PM
- Reuters
NEW YORK, March 21 (Reuters) - Shares of biotechnology companies resumed their steep slide on Tuesday, with Protein Design Labs Inc. (NASDAQ:PDLI) leading the Nasdaq percentage losers after news that one of the drug developer`s European patents had been revoked.
Shares of Protein Design Labs slid 38 percent on the Nasdaq, or 51-15/16, to 82-3/16, by Tuesday afternoon, extending a 26 percent decline by the stock the previous session.
Late Monday, the California drug developer said broad claims on its European patent for humanized monoclonal antibodies had been revoked. It said it planned to press an appeal of the decision over the next several years, during which time the patent decision would be suspended.
The announcement, which came after regular U.S. stock trading, was the latest piece of unfavorable news for a sector that has suffered a sharp setback over the past two weeks. On Tuesday, the Nasdaq biotech index slipped 30.96, or 2.85 percent, at 1056.53, bringing its losses to about 35 percent since March 6. Before then, the index had risen more than 80 percent since the beginning of the year.
The selling pressure spread to a broad range of biotech stocks even though analysts saw no far-reaching negative precedent involved in the European patent ruling and said the outlook for Protein Design Labs remained strong.
"We think this is one of the great all-time buying opportunities, and the event that happened yesterday is completely nonmaterial," said Matthew Geller, senior biotechnology analyst with CIBC World Markets. "The decision has no impact on products sold or manufactured in the United States. So there`s a very questionable dubious impact five or six years from now."
William Tanner, a biotechnology analyst with SG Cowen, said he was still bullish on Protein Design Labs. "We`d upgrade the stock here if we didn`t have a `strong buy` rating on it."
Some analysts, however, thought the Protein Design downturn was unlikely to hurt the sector because the companies use different technologies to make antibodies .
An antibody is a naturally-occurring immune system protein that selectively seeks out and destroys pathogens or other proteins that are deemed "foreign" invaders. They can be harvested and manipulated in the laboratory by so-called recombinant methods for future use as drugs.
Protein Design specializes in making "humanized" antibodies, that have mostly human components, but also traces of mouse antibodies. Abgenix Inc. (NASDAQ:ABGX) and Medarex Inc. (NASDAQ:MEDX) by contrast, grow "fully human" antibodies in mice whose immune systems have been genetically changed to produce antibodies with purely human characteristics and no mouse components.
Antibodies of all types are the rage among drug makers because they are an effective and relatively easy to produce means of treating and preventing disease.
Among other biotech stocks, Myriad Genetics Inc. (NASDAQ:MYGN) was down 44 percent, or 53, at 67; Medarex slid 23 percent, or 15-13/16, to 51; and Antigenics Inc. (NASDAQ:AGEN) was down 24 percent, or 7-1/4, at 22-1/2.
"Everybody was of the consensus that (biotechs) were a little overextended," Tanner said. "The first few months of this year the Nasdaq biotech index went ballistic."
Biotech stocks tumbled last week, falling as much as 14 percent, after U.S. President Bill Clinton and British Prime Minister Tony Blair said scientists worldwide should have free access to research on the mapping of human genes.
Tanner said stocks were now returning to a more realistic value. "It`s not hype so much," he said. "It`s not a house of cards, there`s substance (to the sector)."
War das ein Kniefall, aber solide Unterstützung bei 180, wenigstens das.
TGK
Hallo Leute,
ich muß hier nun mal wieder etwas zu Abgenix schreiben. Dieser Wert scheint im Vergleich zu Medarex total in Vergessenheit geraten zu sein. Dies ist mir unbegreiflich, wo doch Abgenix einige Vorteile gegenüber Medarex zu bieten hat:
-höhere Anzahl von Partnerschaften mit anderen Firmen
-bessere Bewertung durch Analysten in USA
-prognostizierter Break-Even ist früher
-bereits ein Produkt in Phase III und mehrere in II
Wie ist Eure Meinung?
Gruß Greg
ich muß hier nun mal wieder etwas zu Abgenix schreiben. Dieser Wert scheint im Vergleich zu Medarex total in Vergessenheit geraten zu sein. Dies ist mir unbegreiflich, wo doch Abgenix einige Vorteile gegenüber Medarex zu bieten hat:
-höhere Anzahl von Partnerschaften mit anderen Firmen
-bessere Bewertung durch Analysten in USA
-prognostizierter Break-Even ist früher
-bereits ein Produkt in Phase III und mehrere in II
Wie ist Eure Meinung?
Gruß Greg
Schau doch mal auf den Kurs!
Technisch einer besten Werte zur Zeit.
Technisch einer besten Werte zur Zeit.
Abgenix-Artikel zur allgemeinen Kenntnisnahme:
http://cbs.marketwatch.com/archive/20000512/news/current/di…
viel glück, dass ab-geh-nix wieder zu up-wie-nix wird!!!
m.
http://cbs.marketwatch.com/archive/20000512/news/current/di…
viel glück, dass ab-geh-nix wieder zu up-wie-nix wird!!!
m.
Januar: Gliatech,Elan
Februar: Pfizer
März: Corixa, Millenium
Mai: Genzyme Trans.
Heute: SB
Gruß Bogo!
Februar: Pfizer
März: Corixa, Millenium
Mai: Genzyme Trans.
Heute: SB
Gruß Bogo!
Sorry!
Heute: Abbott ????
Gruß Bogo!
Heute: Abbott ????
Gruß Bogo!
Aus dem juchu weekly:
Abgenix Inc. (ABGX) - konnte ein Abkommen mit SmithKline Beecham (SB) bekannt geben. Wie es
weiter hieß, soll SmithKline Abgenix`s XenoMouse Technologie verwenden, um menschliche
Antikörper zu erzeugen. Im Gegenzug wird Abgenix im Rahmen eines Lizenzabkommens Zahlungen
von SmithKline erhalten. SmithKline wird im Rahmen dieser Partnerschaft für die Produktentwicklung
verantwortlich sein. Für Abgenix ist dieser Deal von entscheidender Bedeutung, denn immerhin konnte
mit SmithKline einer der führenden Pharmakonzerne als Partner gewonnen werden und die Akzeptanz
der XenoMouse Technologie eine neue Dimension einleiten.
Anmelden: subscribe@juchu.de -Betreff: juchu weekly anmelden
http://www.juchu.de
Abgenix Inc. (ABGX) - konnte ein Abkommen mit SmithKline Beecham (SB) bekannt geben. Wie es
weiter hieß, soll SmithKline Abgenix`s XenoMouse Technologie verwenden, um menschliche
Antikörper zu erzeugen. Im Gegenzug wird Abgenix im Rahmen eines Lizenzabkommens Zahlungen
von SmithKline erhalten. SmithKline wird im Rahmen dieser Partnerschaft für die Produktentwicklung
verantwortlich sein. Für Abgenix ist dieser Deal von entscheidender Bedeutung, denn immerhin konnte
mit SmithKline einer der führenden Pharmakonzerne als Partner gewonnen werden und die Akzeptanz
der XenoMouse Technologie eine neue Dimension einleiten.
Anmelden: subscribe@juchu.de -Betreff: juchu weekly anmelden
http://www.juchu.de
Wer ist denn bei unserer Abgenix (bzw. in diesem Board) noch dabei? Sieht so aus als sollten wir bald die alten Höhen wieder erreichen! Gutes Umfeld und zuletzt viele gute Meldungen. Wird Zeit das wir den eigentlichen Star im Antikörperberich wieder in Szene setzten.
Gruß Bogo!
Gruß Bogo!
habe ich schon bei LEXICON gepostet aber hier nocheinmal:
Abgenix and Lexicon Genetics Form Alliance for Antibody Drug Discovery Using Knowledge of Human Gene Function Fully Human Antibodies to be Developed for Knockout-Validated Drug Targets
WEDNESDAY, JULY 12, 2000 6:30:00 PM EST
FREMONT, Calif. and THE WOODLANDS, Texas, Jul 12, 2000 /PRNewswire via COMTEX/ -- Abgenix, Inc. ABGX and Lexicon Genetics Incorporated LEXG announced today a drug discovery alliance that will combine Lexicon`s understanding of human gene function with the power of Abgenix`s fully human antibody generation.
Under the terms of the agreement, Lexicon will contribute drug targets that derive from its proprietary portfolio of full-length human genes whose functions are defined using Lexicon`s knockout mouse technology. A joint committee of Abgenix and Lexicon scientists will select from a pool of knockout-validated targets for antibody-based drug discovery. Abgenix will use its proprietary XenoMouse(TM) technology to generate fully human antibodies for each of the drug targets selected by the committee. The companies anticipate that dozens of knockout-validated targets will enter preclinical programs for development into antibody product candidates during their collaboration. Each company will have the right to obtain exclusive commercialization rights, including sublicensing rights, for an equal number of qualifying antibodies. Lexicon and Abgenix will each receive milestone payments and royalties on sales of antibody drugs from the collaboration that are commercialized by the other party or a third party sublicensee. Each company will bear the expense of its own efforts under the collaboration.
"We believe that this new alliance combines two of the most powerful drug discovery technologies available today to find new therapeutic proteins: functional genomics and fully human antibody generation," said Arthur T. Sands, M.D., Ph.D., Lexicon`s President and Chief Executive Officer. "This agreement is a significant component of our drug discovery strategy through partnerships with leading companies in the field of therapeutic proteins. With Lexicon and Abgenix working together in the post-genome era, clearly the mouse is man`s new best friend."
"Lexicon has a portfolio of exciting technologies for identifying novel drug targets," said R. Scott Greer, Chairman and CEO of Abgenix. "We believe that the marriage of Lexicon`s targets with our XenoMouse technology for rapid generation of fully human monoclonal antibodies could result in the discovery and commercialization of multiple novel drugs for many diseases."
Lexicon uses its proprietary technologies to rapidly generate and analyze knockout mice in order to discover knockout-validated genes for pharmaceutical product development. Currently, hundreds of Lexicon`s top priority knockout mice are being evaluated to identify optimal targets for drug discovery or to find genes that encode therapeutic proteins, which may themselves be used as drugs. Families of genes encoding novel receptors, ion channels, proteases, kinases, and secreted proteins are included as knockouts in Lexicon`s drug discovery programs. Such gene families are thought to be of the highest potential commercial value since most drugs act through genes in those categories. Lexicon has developed internal drug discovery programs in the areas of behavior, neurology, developmental biology, cancer and aging, immunology and hematology.
Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank(R) library of tens of thousands of knockout mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery. Lexicon`s Internet exchange, www.lexgen.com enables researchers worldwide to access the OmniBank library and form collaborations with Lexicon to discover pharmaceutical products based on genes and knowledge of their functions. Lexicon has established functional genomics and OmniBank alliances with many pharmaceutical and biotechnology companies including American Home Products, The R.W. Johnson Pharmaceutical Research Institute, G.D. Searle & Co., Boehringer Ingelheim Pharmaceuticals, N.V. Organon, ZymoGenetics/ Novo Nordisk, DuPont Pharmaceuticals and Millennium Pharmaceuticals, Inc. Additional Company information is available at www.lexicon-genetics.com.
Abgenix is a biopharmaceutical company that develops and intends to commercialize antibody therapies for the treatment of such conditions as transplant-related diseases, inflammatory and autoimmune disorders, cardiovascular disease, infectious diseases, and cancer. Abgenix developed XenoMouse technology to enable the rapid generation of high affinity, fully human antibody product candidates to essentially any disease target appropriate for antibody therapy. Abgenix has collaborative arrangements with multiple pharmaceutical, genomics and biotechnology companies involving its XenoMouse technology. In addition, Abgenix has multiple proprietary antibody product candidates under development internally, three of which are in human clinical trials for graft-versus-host disease, psoriasis, rheumatoid arthritis, and cancer. For more information on Abgenix, visit the company`s Web site at www.abgenix.com.
Statements in this press release about Lexicon that are not strictly historical are "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. The actual results may differ materially from those projected in the forward-looking statements due to the risks and uncertainties that exist in Lexicon`s filings with the Securities and Exchange Commission, including risks associated with the progress of research and product development programs, the success of clinical trials, the regulatory approval process, competitive products, future capital requirements and the extent and breadth of Lexicon`s patent portfolio. Lexicon disclaims any obligations to update the statements in this press release.
Statements made in this press release about Abgenix`s XenoMouse technology, product development activities and collaborative arrangements other than statements of historical fact, are forward looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials, the progress of research and product development programs, the regulatory approval process, competitive products, future capital requirements and the extent and breadth of Abgenix`s patent portfolio. Please see Abgenix`s public filings with the Securities and Exchange Commission for information about risks that may affect Abgenix.
SOURCE Abgenix, Inc.
Abgenix and Lexicon Genetics Form Alliance for Antibody Drug Discovery Using Knowledge of Human Gene Function Fully Human Antibodies to be Developed for Knockout-Validated Drug Targets
WEDNESDAY, JULY 12, 2000 6:30:00 PM EST
FREMONT, Calif. and THE WOODLANDS, Texas, Jul 12, 2000 /PRNewswire via COMTEX/ -- Abgenix, Inc. ABGX and Lexicon Genetics Incorporated LEXG announced today a drug discovery alliance that will combine Lexicon`s understanding of human gene function with the power of Abgenix`s fully human antibody generation.
Under the terms of the agreement, Lexicon will contribute drug targets that derive from its proprietary portfolio of full-length human genes whose functions are defined using Lexicon`s knockout mouse technology. A joint committee of Abgenix and Lexicon scientists will select from a pool of knockout-validated targets for antibody-based drug discovery. Abgenix will use its proprietary XenoMouse(TM) technology to generate fully human antibodies for each of the drug targets selected by the committee. The companies anticipate that dozens of knockout-validated targets will enter preclinical programs for development into antibody product candidates during their collaboration. Each company will have the right to obtain exclusive commercialization rights, including sublicensing rights, for an equal number of qualifying antibodies. Lexicon and Abgenix will each receive milestone payments and royalties on sales of antibody drugs from the collaboration that are commercialized by the other party or a third party sublicensee. Each company will bear the expense of its own efforts under the collaboration.
"We believe that this new alliance combines two of the most powerful drug discovery technologies available today to find new therapeutic proteins: functional genomics and fully human antibody generation," said Arthur T. Sands, M.D., Ph.D., Lexicon`s President and Chief Executive Officer. "This agreement is a significant component of our drug discovery strategy through partnerships with leading companies in the field of therapeutic proteins. With Lexicon and Abgenix working together in the post-genome era, clearly the mouse is man`s new best friend."
"Lexicon has a portfolio of exciting technologies for identifying novel drug targets," said R. Scott Greer, Chairman and CEO of Abgenix. "We believe that the marriage of Lexicon`s targets with our XenoMouse technology for rapid generation of fully human monoclonal antibodies could result in the discovery and commercialization of multiple novel drugs for many diseases."
Lexicon uses its proprietary technologies to rapidly generate and analyze knockout mice in order to discover knockout-validated genes for pharmaceutical product development. Currently, hundreds of Lexicon`s top priority knockout mice are being evaluated to identify optimal targets for drug discovery or to find genes that encode therapeutic proteins, which may themselves be used as drugs. Families of genes encoding novel receptors, ion channels, proteases, kinases, and secreted proteins are included as knockouts in Lexicon`s drug discovery programs. Such gene families are thought to be of the highest potential commercial value since most drugs act through genes in those categories. Lexicon has developed internal drug discovery programs in the areas of behavior, neurology, developmental biology, cancer and aging, immunology and hematology.
Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank(R) library of tens of thousands of knockout mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery. Lexicon`s Internet exchange, www.lexgen.com enables researchers worldwide to access the OmniBank library and form collaborations with Lexicon to discover pharmaceutical products based on genes and knowledge of their functions. Lexicon has established functional genomics and OmniBank alliances with many pharmaceutical and biotechnology companies including American Home Products, The R.W. Johnson Pharmaceutical Research Institute, G.D. Searle & Co., Boehringer Ingelheim Pharmaceuticals, N.V. Organon, ZymoGenetics/ Novo Nordisk, DuPont Pharmaceuticals and Millennium Pharmaceuticals, Inc. Additional Company information is available at www.lexicon-genetics.com.
Abgenix is a biopharmaceutical company that develops and intends to commercialize antibody therapies for the treatment of such conditions as transplant-related diseases, inflammatory and autoimmune disorders, cardiovascular disease, infectious diseases, and cancer. Abgenix developed XenoMouse technology to enable the rapid generation of high affinity, fully human antibody product candidates to essentially any disease target appropriate for antibody therapy. Abgenix has collaborative arrangements with multiple pharmaceutical, genomics and biotechnology companies involving its XenoMouse technology. In addition, Abgenix has multiple proprietary antibody product candidates under development internally, three of which are in human clinical trials for graft-versus-host disease, psoriasis, rheumatoid arthritis, and cancer. For more information on Abgenix, visit the company`s Web site at www.abgenix.com.
Statements in this press release about Lexicon that are not strictly historical are "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. The actual results may differ materially from those projected in the forward-looking statements due to the risks and uncertainties that exist in Lexicon`s filings with the Securities and Exchange Commission, including risks associated with the progress of research and product development programs, the success of clinical trials, the regulatory approval process, competitive products, future capital requirements and the extent and breadth of Lexicon`s patent portfolio. Lexicon disclaims any obligations to update the statements in this press release.
Statements made in this press release about Abgenix`s XenoMouse technology, product development activities and collaborative arrangements other than statements of historical fact, are forward looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials, the progress of research and product development programs, the regulatory approval process, competitive products, future capital requirements and the extent and breadth of Abgenix`s patent portfolio. Please see Abgenix`s public filings with the Securities and Exchange Commission for information about risks that may affect Abgenix.
SOURCE Abgenix, Inc.
Die Quartalszahlen brachten gestern an der Nasdaq + 9,9 %:
############
FREMONT, Calif., July 25 /PRNewswire/ via NewsEdge Corporation -- Abgenix, Inc. (Nasdaq: ABGX) reported a net loss of $2.4 million or $0.03 per share for the quarter ended June 30, 2000, compared with a net loss of $3.6 million or $0.06 per share for the quarter ended June 30, 1999. Contract revenues for the quarter were $3.5 million compared to $1.7 million for the same quarter in 1999. The deferred revenue balance at the end of the quarter was $12.5 million. The company ended the second quarter with $555 million in cash, cash equivalents and short-term investments.
Second quarter company highlights included:
-- Entering XenoMouse(TM) technology collaborations with SmithKline Beecham and Abbott. Abgenix now has 21 partners,
-- Announcing the second stock split for the year,
-- Strengthening its intellectual property with the issuance of a second patent for XenoMouse technology,
-- Announcing new key hires: VPs of Manufacturing, Product Discovery and Process Sciences, and
-- Entering a collaboration with Genzyme Transgenics (GTC) to produce ABX-IL8, Abgenix`s fully human antibody in Phase II clinical trials for psoriasis, using GTC`s transgenic manufacturing system.
In addition, Abgenix recently announced an important drug discovery collaboration with Lexicon Genetics, a functional genomics company, to develop fully human antibody therapies using Lexicon`s knockout-validated gene drug targets.
Abgenix is a biopharmaceutical company that develops and intends to commercialize antibody therapies for the treatment of such conditions as transplant-related diseases, inflammatory and autoimmune disorders, cardiovascular disease, infectious diseases, and cancer. For more information on Abgenix, visit the company`s Web site at www.abgenix.com.
Abgenix developed XenoMouse technology to enable the rapid generation of high affinity, fully human antibody product candidates to essentially any disease target appropriate for antibody therapy. Abgenix has collaborative arrangements with multiple pharmaceutical and biotechnology companies involving its XenoMouse technology. In addition, Abgenix has multiple proprietary antibody product candidates under development internally, three of which are in human clinical trials for graft-versus-host disease, psoriasis, rheumatoid arthritis, and cancer.
NOTE: Statements made in this press release about Abgenix`s XenoMouse technology, product development activities and collaborative arrangements other than statements of historical fact, are forward looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials, the progress of research and product development programs, the regulatory approval process, competitive products, future capital requirements and the extent and breadth of Abgenix`s patent portfolio. Please see Abgenix`s public filings with the Securities and Exchange Commission for information about risks which may affect Abgenix.
STATEMENT OF OPERATIONS
(in thousands except per share data)
(unaudited)
Three Months Ended Six Months Ended
June 30, 2000 June 30, 2000
2000 1999 2000 1999
Revenues:
Contract revenues $3,478 $1,720 $5,443 $1,720
Interest income 8,781 797 13,122 1,192
Total revenues 12,259 2,517 18,565 2,912
Costs and Expenses:
Research and development 11,912 5,312 19,126 9,878
General and administrative 1,805 1,210 3,390 2,295
Amortization of intangible
assets 777 -- 1,553 --
Equity in income from
Xenotech joint venture -- (548) -- (540)
Interest expense 185 111 300 244
Total costs and expenses 14,679 6,085 24,369 11,877
Net loss ($2,420) ($3,568) ($5,804) ($8,965)
Basic and diluted net loss
per share * ($0.03) ($0.06) ($0.07) ($0.17)
Shares used in computing
basic and diluted
net loss per share 80,545 59,664 77,522 54,216
June 30, December 31,
BALANCE SHEET 2000 1999
(unaudited)
Cash, cash equivalents
and marketable securities $555,537 $56,909
Other current assets 15,233 10,114
Total current assets 570,770 67,023
Property and equipment, net 6,254 5,300
Long-term investment 31,896 29,225
Intangible assets, net 45,038 46,591
Deposits & other assets 708 402
Total assets $654,666 $148,541
Deferred revenue $12,539 $3,767
Other current liabilities 6,606 7,143
Total current liabilities 19,145 10,910
Long-term debt and other 240 571
Stockholders` equity: 635,281 137,060
Total liabilities and
stockholders` equity $654,666 $148,541
############
FREMONT, Calif., July 25 /PRNewswire/ via NewsEdge Corporation -- Abgenix, Inc. (Nasdaq: ABGX) reported a net loss of $2.4 million or $0.03 per share for the quarter ended June 30, 2000, compared with a net loss of $3.6 million or $0.06 per share for the quarter ended June 30, 1999. Contract revenues for the quarter were $3.5 million compared to $1.7 million for the same quarter in 1999. The deferred revenue balance at the end of the quarter was $12.5 million. The company ended the second quarter with $555 million in cash, cash equivalents and short-term investments.
Second quarter company highlights included:
-- Entering XenoMouse(TM) technology collaborations with SmithKline Beecham and Abbott. Abgenix now has 21 partners,
-- Announcing the second stock split for the year,
-- Strengthening its intellectual property with the issuance of a second patent for XenoMouse technology,
-- Announcing new key hires: VPs of Manufacturing, Product Discovery and Process Sciences, and
-- Entering a collaboration with Genzyme Transgenics (GTC) to produce ABX-IL8, Abgenix`s fully human antibody in Phase II clinical trials for psoriasis, using GTC`s transgenic manufacturing system.
In addition, Abgenix recently announced an important drug discovery collaboration with Lexicon Genetics, a functional genomics company, to develop fully human antibody therapies using Lexicon`s knockout-validated gene drug targets.
Abgenix is a biopharmaceutical company that develops and intends to commercialize antibody therapies for the treatment of such conditions as transplant-related diseases, inflammatory and autoimmune disorders, cardiovascular disease, infectious diseases, and cancer. For more information on Abgenix, visit the company`s Web site at www.abgenix.com.
Abgenix developed XenoMouse technology to enable the rapid generation of high affinity, fully human antibody product candidates to essentially any disease target appropriate for antibody therapy. Abgenix has collaborative arrangements with multiple pharmaceutical and biotechnology companies involving its XenoMouse technology. In addition, Abgenix has multiple proprietary antibody product candidates under development internally, three of which are in human clinical trials for graft-versus-host disease, psoriasis, rheumatoid arthritis, and cancer.
NOTE: Statements made in this press release about Abgenix`s XenoMouse technology, product development activities and collaborative arrangements other than statements of historical fact, are forward looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials, the progress of research and product development programs, the regulatory approval process, competitive products, future capital requirements and the extent and breadth of Abgenix`s patent portfolio. Please see Abgenix`s public filings with the Securities and Exchange Commission for information about risks which may affect Abgenix.
STATEMENT OF OPERATIONS
(in thousands except per share data)
(unaudited)
Three Months Ended Six Months Ended
June 30, 2000 June 30, 2000
2000 1999 2000 1999
Revenues:
Contract revenues $3,478 $1,720 $5,443 $1,720
Interest income 8,781 797 13,122 1,192
Total revenues 12,259 2,517 18,565 2,912
Costs and Expenses:
Research and development 11,912 5,312 19,126 9,878
General and administrative 1,805 1,210 3,390 2,295
Amortization of intangible
assets 777 -- 1,553 --
Equity in income from
Xenotech joint venture -- (548) -- (540)
Interest expense 185 111 300 244
Total costs and expenses 14,679 6,085 24,369 11,877
Net loss ($2,420) ($3,568) ($5,804) ($8,965)
Basic and diluted net loss
per share * ($0.03) ($0.06) ($0.07) ($0.17)
Shares used in computing
basic and diluted
net loss per share 80,545 59,664 77,522 54,216
June 30, December 31,
BALANCE SHEET 2000 1999
(unaudited)
Cash, cash equivalents
and marketable securities $555,537 $56,909
Other current assets 15,233 10,114
Total current assets 570,770 67,023
Property and equipment, net 6,254 5,300
Long-term investment 31,896 29,225
Intangible assets, net 45,038 46,591
Deposits & other assets 708 402
Total assets $654,666 $148,541
Deferred revenue $12,539 $3,767
Other current liabilities 6,606 7,143
Total current liabilities 19,145 10,910
Long-term debt and other 240 571
Stockholders` equity: 635,281 137,060
Total liabilities and
stockholders` equity $654,666 $148,541
Neues vom Marktführer:
Robertson u. Stephens wiederholt strong buy für Abgenix, desweiteren hat Abgenix ein globales Abkommen mit SangStat zur Vermarktung und Entwicklung eines seiner Produkte (für Transplantation) getroffen.
Gruß Bogo!
Robertson u. Stephens wiederholt strong buy für Abgenix, desweiteren hat Abgenix ein globales Abkommen mit SangStat zur Vermarktung und Entwicklung eines seiner Produkte (für Transplantation) getroffen.
Gruß Bogo!
FREMONT, Calif.--(BW HealthWire)--Aug. 8, 2000--Abgenix, Inc. (Nasdaq:ABGX), and SangStat, The Transplant Company,(R), (Nasdaq:SANG) reported today that they have entered into a global co-development, supply and license agreement for ABX-CBL, an antibody developed by Abgenix. SangStat will have an exclusive worldwide license for the marketing and sale of ABX-CBL and, subject to the terms and conditions of the agreement, the right to commercialize other anti-CD147 antibodies. Abgenix will be responsible for manufacturing ABX-CBL.
"Abgenix is pleased to be collaborating with SangStat, a leading supplier of products and services in the transplant field," said R. Scott Greer, chairman and CEO of Abgenix. "We believe SangStat has the development and commercialization experience to maximize the potential of ABX-CBL, which is in a Phase II/III clinical trial for steroid resistant GVHD."
"This is a very exciting development for SangStat and is a great fit with our expertise in specialized marketing and our efforts to expand into other therapeutic areas," said Jean-Jacques Bienaime, President and CEO of SangStat. "We look forward to working with Abgenix on the development of ABX-CBL and potentially a next generation anti-CD147 product.
"Under the agreement, SangStat will make an initial license fee payment and additional milestone payments to Abgenix. Development costs will be shared equally, as would any potential profits from sales of collaboration products. SangStat and Abgenix will share responsibility for product development, including the ongoing trial.
ABX-CBL is an anti-CD147 monoclonal antibody for the treatment of steroid resistant graft versus host disease (GVHD) and is currently in a multicenter, randomized, and controlled Phase II/III study. The study is designed to demonstrate statistically significant efficacy of a single dose level of ABX CBL in comparison to a control group of patients. In an earlier Phase II trial completed in the fall of 1999, 52% of patients receiving 0.1 - 0.3 mg/kg ABX-CBL survived at least 100 days following initiation of therapy, compared to 22% of patients receiving the presumed no effect dose of 0.01 mg/kg. Approximately 25% of patients that undergo an allogeneic bone marrow transplant develop steroid resistant GVHD for which there is currently no standard approved therapy available.
SangStat shall have the right to commercialize any anti-CD147 antibody developed by Abgenix, subject to certain terms and conditions of the agreement, including ABX-RB2, the next generation fully human antibody to CD 147, generated with Abgenix`s proprietary XenoMouse(TM) technology. ABX-RB2 is currently in pre-clinical development with potential target indications beyond GVHD, including solid organ transplantation and autoimmune diseases such as rheumatoid arthritis. Abgenix Inc.
Abgenix is a biopharmaceutical company that develops and intends to commercialize antibody therapies for the treatment of such conditions as transplant-related diseases, inflammatory and autoimmune disorders, cardiovascular disease, infectious diseases, and cancer. For more information on Abgenix, visit the company`s Web site at www.abgenix.com.
Abgenix developed XenoMouse technology to enable the rapid generation of high affinity, fully human antibody product candidates to essentially any disease target appropriate for antibody therapy. Abgenix has collaborative arrangements with multiple pharmaceutical, genomics and biotechnology companies involving its XenoMouse technology. In addition, Abgenix has multiple proprietary antibody product candidates under development internally, three of which are in human clinical trials for graft-versus-host disease, psoriasis, rheumatoid arthritis, and cancer. SangStat, The Transplant Company(R)
SangStat, The Transplant Company(R), is a global bio-pharmaceutical company applying a disease management approach to improving the outcome of organ, bone marrow, and stem cell transplantation. Since 1988, we have built a family of products and services to address the pre-transplant, acute care and chronic phases of transplant in the worldwide market. SangStat`s The Transplant Pharmacy, is a dedicated mail order pharmacy that provides direct drug distribution and patient-focused management services. TransplantRx.com was introduced in 1999 as an on-line component and one-stop-shop providing e-commerce, content, and community for transplant recipients and providers. The company`s long-term goal is to expand this success in transplantation to the broader immunosuppressive market.
Statements made in this press release about Abgenix`s XenoMouse technology, product development activities and collaborative arrangements, other than statements of historical fact, are forward looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials, the progress of research and product development programs, the regulatory approval process, competitive products, future capital requirements and the extent and breadth of Abgenix`s patent portfolio. Please see Abgenix`s public filings with the Securities and Exchange Commission for information about risks that may affect Abgenix.
This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding the company`s (1) commitments, intents and goals, and (2) potential future sales, marketing efforts and product development. Forward-looking statements reflect SangStat`s current views with respect to future events. Actual results may vary materially and adversely from those anticipated, believed, estimated, or otherwise indicated. In addition, competitive pressures, manufacturing or supply interruptions, regulatory matters, marketing or pricing actions, other generic competition, reimbursement practices of third party payors, product liability claims or other factors could adversely impact sales of the products; and there can be no assurance that any product candidate under development will be safe, effective or capable of being manufactured in commercial quantities at an economical cost, or that any product will not infringe the proprietary rights of others or will achieve market acceptance. Other factors that could cause actual results to differ materially include, without limitation, the expenses associated with and uncertainty related to the lawsuits pending against the MCA by Novartis with respect to SangCya oral solution. For a discussion of these and other factors that might result in different outcomes, see "Risk Factors" in SangStat`s 1999 Annual Report on Form 10-K and 2000 Form 10-Qs filed with the Securities and Exchange Commission.
You can find full copies of the prescribing information for Thymoglobulin and Gengraf and copies of our latest press releases on the web at www.sangstat.com.
Strong Buy
Jay Silverman, Biopharmaceuticals
"Abgenix has entered into another 50/50 partnership, this time with SangStat, to develop its Phase II/III antibody, ABX-CBL," said Silverman. "We believe the partnership is another example of Abgenix`s commitment to form 50/50 collaborations in order to develop its own drug product portfolio and become an integrated biopharmaceuticals company. We reiterate our Strong Buy rating."
Gruß Bogo!
"Abgenix is pleased to be collaborating with SangStat, a leading supplier of products and services in the transplant field," said R. Scott Greer, chairman and CEO of Abgenix. "We believe SangStat has the development and commercialization experience to maximize the potential of ABX-CBL, which is in a Phase II/III clinical trial for steroid resistant GVHD."
"This is a very exciting development for SangStat and is a great fit with our expertise in specialized marketing and our efforts to expand into other therapeutic areas," said Jean-Jacques Bienaime, President and CEO of SangStat. "We look forward to working with Abgenix on the development of ABX-CBL and potentially a next generation anti-CD147 product.
"Under the agreement, SangStat will make an initial license fee payment and additional milestone payments to Abgenix. Development costs will be shared equally, as would any potential profits from sales of collaboration products. SangStat and Abgenix will share responsibility for product development, including the ongoing trial.
ABX-CBL is an anti-CD147 monoclonal antibody for the treatment of steroid resistant graft versus host disease (GVHD) and is currently in a multicenter, randomized, and controlled Phase II/III study. The study is designed to demonstrate statistically significant efficacy of a single dose level of ABX CBL in comparison to a control group of patients. In an earlier Phase II trial completed in the fall of 1999, 52% of patients receiving 0.1 - 0.3 mg/kg ABX-CBL survived at least 100 days following initiation of therapy, compared to 22% of patients receiving the presumed no effect dose of 0.01 mg/kg. Approximately 25% of patients that undergo an allogeneic bone marrow transplant develop steroid resistant GVHD for which there is currently no standard approved therapy available.
SangStat shall have the right to commercialize any anti-CD147 antibody developed by Abgenix, subject to certain terms and conditions of the agreement, including ABX-RB2, the next generation fully human antibody to CD 147, generated with Abgenix`s proprietary XenoMouse(TM) technology. ABX-RB2 is currently in pre-clinical development with potential target indications beyond GVHD, including solid organ transplantation and autoimmune diseases such as rheumatoid arthritis. Abgenix Inc.
Abgenix is a biopharmaceutical company that develops and intends to commercialize antibody therapies for the treatment of such conditions as transplant-related diseases, inflammatory and autoimmune disorders, cardiovascular disease, infectious diseases, and cancer. For more information on Abgenix, visit the company`s Web site at www.abgenix.com.
Abgenix developed XenoMouse technology to enable the rapid generation of high affinity, fully human antibody product candidates to essentially any disease target appropriate for antibody therapy. Abgenix has collaborative arrangements with multiple pharmaceutical, genomics and biotechnology companies involving its XenoMouse technology. In addition, Abgenix has multiple proprietary antibody product candidates under development internally, three of which are in human clinical trials for graft-versus-host disease, psoriasis, rheumatoid arthritis, and cancer. SangStat, The Transplant Company(R)
SangStat, The Transplant Company(R), is a global bio-pharmaceutical company applying a disease management approach to improving the outcome of organ, bone marrow, and stem cell transplantation. Since 1988, we have built a family of products and services to address the pre-transplant, acute care and chronic phases of transplant in the worldwide market. SangStat`s The Transplant Pharmacy, is a dedicated mail order pharmacy that provides direct drug distribution and patient-focused management services. TransplantRx.com was introduced in 1999 as an on-line component and one-stop-shop providing e-commerce, content, and community for transplant recipients and providers. The company`s long-term goal is to expand this success in transplantation to the broader immunosuppressive market.
Statements made in this press release about Abgenix`s XenoMouse technology, product development activities and collaborative arrangements, other than statements of historical fact, are forward looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials, the progress of research and product development programs, the regulatory approval process, competitive products, future capital requirements and the extent and breadth of Abgenix`s patent portfolio. Please see Abgenix`s public filings with the Securities and Exchange Commission for information about risks that may affect Abgenix.
This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding the company`s (1) commitments, intents and goals, and (2) potential future sales, marketing efforts and product development. Forward-looking statements reflect SangStat`s current views with respect to future events. Actual results may vary materially and adversely from those anticipated, believed, estimated, or otherwise indicated. In addition, competitive pressures, manufacturing or supply interruptions, regulatory matters, marketing or pricing actions, other generic competition, reimbursement practices of third party payors, product liability claims or other factors could adversely impact sales of the products; and there can be no assurance that any product candidate under development will be safe, effective or capable of being manufactured in commercial quantities at an economical cost, or that any product will not infringe the proprietary rights of others or will achieve market acceptance. Other factors that could cause actual results to differ materially include, without limitation, the expenses associated with and uncertainty related to the lawsuits pending against the MCA by Novartis with respect to SangCya oral solution. For a discussion of these and other factors that might result in different outcomes, see "Risk Factors" in SangStat`s 1999 Annual Report on Form 10-K and 2000 Form 10-Qs filed with the Securities and Exchange Commission.
You can find full copies of the prescribing information for Thymoglobulin and Gengraf and copies of our latest press releases on the web at www.sangstat.com.
Strong Buy
Jay Silverman, Biopharmaceuticals
"Abgenix has entered into another 50/50 partnership, this time with SangStat, to develop its Phase II/III antibody, ABX-CBL," said Silverman. "We believe the partnership is another example of Abgenix`s commitment to form 50/50 collaborations in order to develop its own drug product portfolio and become an integrated biopharmaceuticals company. We reiterate our Strong Buy rating."
Gruß Bogo!
Neue Meldung vom Marktführer bezüglich des Abkommens mit CuraGen:
NEW YORK, Aug 15 (Reuters) - CuraGen Corp. <CRGN.O>, a genomics-based drug discovery and development company, and Abgenix Inc. <ABGX.O> said on Tuesday the companies selected 24 antibody drug targets for further evaluation and possible development as cancer therapeutics.
The companies are collaborating on developing up to 120 antibody drug candidates against cancer, inflammation and autoimmune diseases under a five-year program that started seven months ago.
Abgenix will apply its XenoMouse technology to produce fully human antibodies directed against antibody drug targets discovered by New Haven, Conn.-based CuraGen.
After the drug targets are identified, representatives of each company will select the most promising drug targets, which will be tested for efficacy against cancer in pre-clinical trials.
CuraGen is using its Internet-based technologies and genomics expertise to discover protein and antibody drugs, and small molecule drug targets for development within the company`s internal disease programs. CuraGen is actively developing therapeutics to treat obesity and diabetes, cancer, inflammatory diseases, and psychiatric disorders.
Fremont, Calif.-based Abgenix developed XenoMouse technology to generate fully human antibody product candidates to target diseases.
Gruß Bogo!
NEW YORK, Aug 15 (Reuters) - CuraGen Corp. <CRGN.O>, a genomics-based drug discovery and development company, and Abgenix Inc. <ABGX.O> said on Tuesday the companies selected 24 antibody drug targets for further evaluation and possible development as cancer therapeutics.
The companies are collaborating on developing up to 120 antibody drug candidates against cancer, inflammation and autoimmune diseases under a five-year program that started seven months ago.
Abgenix will apply its XenoMouse technology to produce fully human antibodies directed against antibody drug targets discovered by New Haven, Conn.-based CuraGen.
After the drug targets are identified, representatives of each company will select the most promising drug targets, which will be tested for efficacy against cancer in pre-clinical trials.
CuraGen is using its Internet-based technologies and genomics expertise to discover protein and antibody drugs, and small molecule drug targets for development within the company`s internal disease programs. CuraGen is actively developing therapeutics to treat obesity and diabetes, cancer, inflammatory diseases, and psychiatric disorders.
Fremont, Calif.-based Abgenix developed XenoMouse technology to generate fully human antibody product candidates to target diseases.
Gruß Bogo!
Hohes Handelsvolumen und ein dickes Plus beim Marktführer Gruß an die Fondsmanager!
Bogo!
Im Einklang mit einer Vielzahl weiterer – zuvor sehr hoch be-werteter – Biotech-Unternehmen trat ABGENIX vor Jahres-frist zu einer rasanten Talfahrt an, in deren Verlauf die Aktie der im kalifornischen Freemont beheimateten Company rund drei Viertel des Weges gen Normal-Null zurücklegte. Mittler-weile deutet allerdings vieles darauf hin, dass das auf die Ent-wicklung monoklonaler Antikörper spezialisierte Unternehmen nicht auf Meeresniveau ankommen wird. So konnte sich der Wert in der abgelaufenen Woche deutlich nach oben schwin-gen. Beflügelt wurde der Kurs durch positive Ergebnisse einer vorklinischen Studie. Mittels gentechnisch veränderter Mäuse konnte Abgenix nachweisen, dass der humane Antikörper ABX-IL8 die Angiogenese und das Wachstum menschlicher Krebszellen hemmt. Weiteren Auftrieb
verlieh eine unlängst vereinbarte Kooperation mit der britischen CELLTECH, die wie PFIZER und AMGEN auf das von Abgenix entwickelte Antikörperausleseverfahren zurückgreifen.
verlieh eine unlängst vereinbarte Kooperation mit der britischen CELLTECH, die wie PFIZER und AMGEN auf das von Abgenix entwickelte Antikörperausleseverfahren zurückgreifen.
Der Kursanstieg ist ausgelöst worden durch Insiderkäufe, nach Bekantgabe gab es einen weiteren Rutsch nach oben!
Gruß Bogo!
Gruß Bogo!
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 225 | ||
| 159 | ||
| 87 | ||
| 85 | ||
| 73 | ||
| 49 | ||
| 49 | ||
| 48 | ||
| 47 | ||
| 36 |
| Wertpapier | Beiträge | |
|---|---|---|
| 33 | ||
| 29 | ||
| 28 | ||
| 24 | ||
| 24 | ||
| 23 | ||
| 23 | ||
| 20 | ||
| 19 | ||
| 19 |
